Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxycodone
Drug ID BADD_D01645
Description Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917.[A178696] It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.[L6460]
Indications and Usage Oxycodone is indicated for the treatment of moderate to severe pain.[Label] There is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label]
Marketing Status approved; illicit; investigational
ATC Code N02AA05
DrugBank ID DB00497
KEGG ID D05312
MeSH ID D010098
PubChem ID 5284603
TTD Drug ID D07WPQ
NDC Product Code 71335-0981; 67651-0304; 67651-0305; 67651-0306; 24510-140; 71335-1080; 0904-6966; 24510-130; 65162-048; 67877-625; 71335-0677; 65162-050; 0904-7180; 65162-047; 72162-1812; 67877-623; 67651-0302; 65162-049; 67651-0303; 65162-051; 24510-110; 24510-115; 71335-1023; 24510-120; 72162-1811
UNII CD35PMG570
Synonyms Oxycodone | Dihydrone | Oxycone | Dihydrohydroxycodeinone | Oxycodeinon | Eucodal | Theocodin | Oxycodone Hydrochloride | Oxycontin | Pancodine | Dinarkon | Oxiconum
Chemical Information
Molecular Formula C18H21NO4
CAS Registry Number 76-42-6
SMILES CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Emotional distress19.04.02.0080.187997%Not Available
Psychomotor skills impaired19.22.01.002; 17.02.10.0050.000062%Not Available
Precancerous skin lesion23.01.06.0040.000021%Not Available
General physical health deterioration08.01.03.018--Not Available
Balance disorder08.01.03.081; 17.02.02.007--Not Available
Cardiac death08.04.01.007; 02.03.04.0150.000041%Not Available
Sudden onset of sleep17.15.04.0030.000021%Not Available
Lumbar radiculopathy17.10.03.0030.000021%Not Available
Subileus07.13.01.0040.000031%Not Available
Deep vein thrombosis24.01.02.003--Not Available
Self-injurious ideation19.12.01.007--Not Available
Dyschezia07.02.03.0050.000021%Not Available
Therapy naive08.06.01.029--Not Available
Spondyloarthropathy15.01.09.003--Not Available
Ureteral spasm20.06.01.002--Not Available
Lymphatic disorder01.09.01.003--Not Available
Drug tolerance08.06.01.0030.000313%Not Available
Drug tolerance increased08.06.01.0040.000118%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Organ failure08.01.03.0410.000041%Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.001--Not Available
Affect lability19.04.01.001--Not Available
Dental discomfort07.09.06.0020.000031%Not Available
Brain cancer metastatic17.20.04.001; 16.30.04.001--Not Available
Haemorrhage24.07.01.002--Not Available
Fluid intake reduced14.05.10.0010.000041%Not Available
Faecaloma07.01.03.0040.000083%Not Available
Faecalith07.01.03.0070.000021%Not Available
Bipolar disorder19.16.01.003--Not Available
Major depression19.15.01.0030.000166%Not Available
The 12th Page    First    Pre   12 13 14 15 16    Next   Last    Total 16 Pages